Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Assets (2022 - 2025)

Historic Current Assets for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $137.7 million.

  • Century Therapeutics' Current Assets fell 3315.39% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year decrease of 3315.39%. This contributed to the annual value of $194.1 million for FY2024, which is 963.7% up from last year.
  • As of Q3 2025, Century Therapeutics' Current Assets stood at $137.7 million, which was down 3315.39% from $160.2 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Current Assets high stood at $383.8 million for Q2 2022, and its period low was $137.7 million during Q3 2025.
  • Over the past 4 years, Century Therapeutics' median Current Assets value was $199.8 million (recorded in 2024), while the average stood at $231.3 million.
  • As far as peak fluctuations go, Century Therapeutics' Current Assets tumbled by 5797.73% in 2023, and later skyrocketed by 2616.44% in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' Current Assets stood at $319.7 million in 2022, then tumbled by 44.64% to $177.0 million in 2023, then increased by 9.64% to $194.1 million in 2024, then dropped by 29.03% to $137.7 million in 2025.
  • Its Current Assets was $137.7 million in Q3 2025, compared to $160.2 million in Q2 2025 and $169.6 million in Q1 2025.